Insight

Photo from Aren Karapetyan/LinkedIn

Sep 24, 2024, 08:51

Aren Karapetyan: New Insights on Treatment for Squamous Cell Carcinoma of the Anus

Aren Karapetyan, Oncology Resident at Yerevan State Medical University, shared a post on LinkedIn:

“New Insights on Treatment for Squamous Cell Carcinoma of the Anus (SCCA).

A recent study explores the use of weekly cisplatin as a chemoradiotherapy (CRT) option for SCCA, offering promising results with reduced toxicity compared to traditional regimens.

Key findings:

Safe and effective: Weekly cisplatin showed an acceptable acute toxicity profile and good outcomes.
Improved compliance: Lower hematological toxicity was observed compared to historical data.
Positive outcomes: 5-year Disease-Free Survival (DFS) was 77%, with Overall Survival (OS) at 86%.
This approach may offer a more tolerable option for patients while maintaining high treatment efficacy.”

“Feasibility of weekly cisplatin and radiotherapy for localized anal cancer – A Danish anal cancer group report”

Authors: Anne Vittrup Jakobsen, Camilla Jensenius Skovhus Kronborg, Rikke Kjer Oksen, Birgitte Mayland Havelund, Karen Lycke Wind, Karen-Lise Garm Spindler

Aren Karapetyan: New Insights on Treatment for Squamous Cell Carcinoma of the Anus

Source: Aren Karapetyan/LinkedIn

More posts featuring Aren Karapetyan on oncodaily.com

Anne Vittrup Jakobsen Aren Karapetyan Birgitte Mayland Havelund Camilla Jensenius Skovhus Kronborg cancer chemoradiotherapy Cisplatin CRT Karen Lycke Wind Karen-Lise Garm Spindler OncoDaily Oncology Radiotherapy and Oncology Rikke Kjer Oksen SCCA

Senator Edward Markley in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity